Head to head · SEC data as of July 18, 2026
Stryker
77
Quality score · out of 100
Boston Scientific
84
Quality score · out of 100
Boston Scientific comes in ahead: a quality score of 84 versus 77 for Stryker. Boston Scientific wins on net margin (17.3% vs 13.2%), gross margin (69.2% vs 63.8%) and revenue growth (15% vs 11.4%). Stryker doesn't take a single major metric today.
| Metric | Stryker | Boston Scientific |
|---|---|---|
| Quality score (0-100) | 77 | 84 |
| Net margin | 13.2% | 17.3% |
| Gross margin | 63.8% | 69.2% |
| ROE | 14.5% | 13.8% |
| Net debt/EBITDA | 1.8× | 1.85× |
| FCF margin | 18.1% | 16.9% |
| Revenue growth (annualized) | 11.4% | 15% |
| Earnings growth (annualized) | 14.7% | 34% |
TTM metrics with official SEC data, refreshed daily. Bold green marks the winner of each metric. A dash means the metric doesn't apply or isn't reliable.
Stryker. Stryker is one of the world's largest medical-device makers. It sells implants (hips, knees), surgical equipment, robots for orthopedic surgery and hospital supplies. Its business grows with an aging population and rising surgery volumes.
Boston Scientific. Boston Scientific makes minimally invasive medical devices: stents, catheters, pacemakers and tools for cardiology, endoscopy and urology. Its products are used in millions of procedures a year in hospitals worldwide.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
What this comparison doesn't tell you
The score measures business quality, not whether the stock is cheap or expensive: the better company can be the worse investment if you overpay. For the valuation verdict, enter each one's current price in the analyzer:
Who has the stronger fundamentals today, Stryker or Boston Scientific?
By the StockSemáforo model (profitability, growth and financial strength, built on official SEC data), Boston Scientific scores higher: 84 versus 77 out of 100. The score is recomputed nightly with the latest filings.
Does that make Boston Scientific the better investment?
No. The score measures business quality, not valuation: an excellent company can trade at an excessive price and be a poor investment at that price. To find out whether it's cheap or expensive, enter its current quote in the StockSemáforo analyzer.
Other comparisons
Pfizer vs Merck · Johnson & Johnson vs Pfizer · Eli Lilly vs AbbVie · Amgen vs Gilead · UnitedHealth vs CVS Health · See all comparisons →
Who's behind the methodology and model · how the score is computed
Data: official SEC filings (EDGAR) · Recomputed on July 18, 2026
Spotted a figure that looks wrong? Report it and we'll review it.